Pelaz A, Junquera L, Gallego L, García-Consuegra L, Junquera S, Gómez C. Alternative treatments
for oral bisphosphonate-related osteonecrosis
of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide. Med Oral Patol Oral
Cir Bucal. 2014 Jul 1;19 (4):e320-6.
doi:10.4317/medoral.19458
http://dx.doi.org/doi:10.4317/medoral.19458
|
1. Marx
RE. Pamidronate (Aredia)
and zoledronate (Zometa)
induced avascular necrosis of the jaws: a growing
epidemic. J Oral Maxillofac Surg. 2003;61:1115-7. |
|
|
|
|
|
2. Bagán
JV, Murillo J, Jimenez Y, Poveda
R, Milian MA, Sanchis JM,
et al. Avascular jaw osteonecrosis in association with cancer
chemotherapy: series of 10 cases. J Oral Pathol
Med. 2005;34:120-3. |
|
|
|
|
|
3. Junquera LM, Gallego L, Cuesta
P, Pelaz A, de Vicente JC. Clinical experiences with bisphosphonateassociated
osteonecrosis of the jaws: analysis of 21 cases. Am
J Otolaryngol. 2009;30:390-5.
4. Ruggiero SL. Emerging concepts in the management and treatment of osteonecrosis of the jaw. Oral
Maxillofac Surg Clin North Am. 2013;25:11-20. |
|
|
|
|
|
5. Allen
MR, Burr DB. The pathogenesis of bisphosphonate-related
osteonecrosis of the jaw: so many hypotheses, so
few data. J Oral Maxillofac Surg. 2009;67:61-70. |
|
|
|
|
|
6. Allen
MR, Chu TM, Ruggiero SL. Absence of exposed bone following dental extraction
in beagle dogs treated with 9 months of high-dose zoledronic
acid combined with dexamethasone. J Oral Maxillofac Surg. 2013;71:1017-26.
7. Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW,
et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis
of the jaw: A randomized controlled trial of hyperbaric oxygen as an adjunct
to surgery and antibiotics. J Oral Maxillofac Surg.
2012;70:1573-83. |
|
|
|
|
|
8. Pautke C, Bauer F, Otto S, Tischer
T, Steiner T, Weitz J, et
al. Fluorescence-guided bone resection in bisphosphonate-related
osteonecrosis of the jaws: first clinical results
of a prospective pilot study. J Oral Maxillofac Surg. 2011;69:84-91. |
|
|
|
|
|
9. Vescovi
P, Meleti M, Merigo E, Manfredi M, Fornaini C, Guidotti R, et al. Case series of 589 tooth extractions in
patients under bisphosphonates therapy. Proposal of
a clinical protocol supported by Nd:YAG
low-level laser therapy. Med Oral Patol Oral Cir Bucal. 2013;18:e680-5. |
|
|
|
|
|
10. Gallego L, Junquera L, Pelaz A, Hernando J, Megías J.
The use of pedicled buccal
fat pad combined with sequestrectomy in bisphosphonate-related osteonecrosis
of the maxilla. Med Oral Patol Oral Cir Bucal. 2012;17:e236-41. 11.
Cheung A, Seeman E. Teriparatide
therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med. 2010;363:2473-4. |
|
|
|
|
|
12.
Subramanian G, Cohen HV, Quek SYP A model for the
pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide's
potential role in its resolution. Oral Surg Oral
Med Oral Pathol Oral Radiol
Endod. 2011;112:744-53. |
|
|
|
|
|
15.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra
B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis
of the jaws-2009 update. J Oral Maxillofac
Surg. 2009;67:2-12. |
|
|
|
|
|
16. Ruggiero
SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for
diagnosis, staging and management. Oral Surg Oral
Med Oral Pathol Oral Radiol
Endod. 2006;102:433-41. |
|
|
|
|
|
17. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T.
Classification of platelet concentrates: from pure platelet-rich plasma
(P-PRP) to leucocyte- and platelet-rich fibrin
(L-PRF). Trends Biotechnol. 2009;27:158-67. |
|
|
|
|
|
18. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated
osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent
Assoc. 2007;138:971-7. |
|
|
|
|
|
19. Lee
CY, David T, Nishime M. Use of platelet-rich plasma
in the management of oral biphosphonate- associated
osteonecrosis of the jaw: a report of 2 cases. J
Oral Implantol. 2007;33:371-82.
20. Curi MM, Cossolin GS,
Koga DH, Zardetto C, Christianini
S, Feher O. et al. Bisphosphonate-related
osteonecrosis of the jaws--an initial case series
report of treatment combining partial bone resection and autologous
platelet-rich plasma. J Oral Maxillofac
Surg. 2011;69:2465-72. |
|
|
|
|
|
21. Anitua E, Bego-a L, Orive G. Treatment of hemimandibular
paresthesia in a patient with bisphosphonate-related
osteonecrosis of the jaw (BRONJ) by combining
surgical resection and PRGF-Endoret. Br J Oral Maxillofac Surg. 2012;51:e272-4.
22. Fahrleitner-Pammer A, Langdahl
BL, Marin F, Jakob F, Karras
D, Barrett A. et al. Fracture rate and back pain during and after
discontinuation of teriparatide: 36-month data from
the European Forsteo Observational Study (EFOS). Osteoporos Int. 2011;22:2709-19. |
|
|
|
|
|
23. Liu H,
Michaud K, Nayak S, Karpf
DB, Owens DK, Garber AM. The cost-effectiveness of therapy with teriparatide and alendronate in
women with severe osteoporosis. Arch Intern Med. 2006;166:1209-17. |
|
|
|
|
|
24. Bashutski JD, Eber RM, Kinney
JS, Benavides E, Maitra S, Braun TM, et al. Teriparatide and osseous regeneration in the oral cavity.
N Engl J Med. 2010;363:2396-405. |
|
|
|
|
|
25. Kwon
Y-D, Lee DW, Choi BJ, Lee JW, Kim DY. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis
of the jaws. Osteoporos Int. 2012;23:2721-5. |
|
|
|
|
|
26. Narváez J, Narváez JA, Gomez-Vaquero C, Nolla JM. Lack of response to teriparatide therapy for bisphosphonate-associated
osteonecrosis of the jaw. Osteoporos Int. 2013;24:731-3. |
|
|
|
|
|
27. Narongroeknawin P, Danila MI,
Humphreys LG Jr, Barasch
A, Curtis JR. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case
report. Spec Care Dentist. 2010;30:77-82. |
|
|
|
|
|
28. Harper
RP, Fung E. Resolution of bisphosphonate-associated
osteonecrosis of the mandible: possible application
for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg.
2007;65:573-80. |
|
|
|
|
|
29. Tsai
KY, Huang CS, Huang GM, Yu CT. More on the resolution of bisphosphonate-associated
osteonecrosis of the jaw. J Rheumatol. 2010;37:675. |
|
|
|
|
|
30. Ohbayashi Y, Miyake M, Sawai F,
Minami Y, Iwasaki A, Matsui Y. Adjunct teriparatide
therapy with monitoring of bone turnover markers and bone scintigraphy
for bisphosphonate-related osteonecrosis
of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:e31-7. |
|